107 related articles for article (PubMed ID: 38767987)
1. Optimizing abemaciclib-induced diarrhea management in patients with breast cancer: a pragmatic 2-group study using a postbiotic microbiota stabilizer.
De Sanctis R; Tiberio P; Jacobs F; Gaudio M; Benvenuti C; Giordano L; Torrisi R; Zambelli A; Pozzi C; Penna G; Santoro A; Rescigno M
Oncologist; 2024 May; ():. PubMed ID: 38767987
[TBL] [Abstract][Full Text] [Related]
2. Management of Abemaciclib-Associated Adverse Events in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3.
Rugo HS; Huober J; García-Sáenz JA; Masuda N; Sohn JH; Andre VAM; Barriga S; Cox J; Goetz M
Oncologist; 2021 Jan; 26(1):e53-e65. PubMed ID: 32955138
[TBL] [Abstract][Full Text] [Related]
3. Sticking to the Rules: Outcome and Success Rate of Guideline-Based Diarrhea Management in Metastatic Breast Cancer Patients Treated with Abemaciclib.
Jacobs F; Agostinetto E; Solferino A; Torrisi R; Masci G; Santoro A; De Sanctis R
J Clin Med; 2023 Feb; 12(5):. PubMed ID: 36902563
[TBL] [Abstract][Full Text] [Related]
4. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial.
Johnston SRD; Toi M; O'Shaughnessy J; Rastogi P; Campone M; Neven P; Huang CS; Huober J; Jaliffe GG; Cicin I; Tolaney SM; Goetz MP; Rugo HS; Senkus E; Testa L; Del Mastro L; Shimizu C; Wei R; Shahir A; Munoz M; San Antonio B; André V; Harbeck N; Martin M;
Lancet Oncol; 2023 Jan; 24(1):77-90. PubMed ID: 36493792
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study.
Rugo HS; O'Shaughnessy J; Boyle F; Toi M; Broom R; Blancas I; Gumus M; Yamashita T; Im YH; Rastogi P; Zagouri F; Song C; Campone M; San Antonio B; Shahir A; Hulstijn M; Brown J; Zimmermann A; Wei R; Johnston SRD; Reinisch M; Tolaney SM;
Ann Oncol; 2022 Jun; 33(6):616-627. PubMed ID: 35337972
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of abemaciclib-based therapy versus tucidinostat-based therapy after progression on palbociclib in patients with HR
Yuan Y; Zhang S; Wang T; Wang B; Wang S; Shi J; Sun T; Yin Y; Ouyang Q; Li J; Wen Y; Zhang L; Jiang Z
Transl Breast Cancer Res; 2023; 4():10. PubMed ID: 38751483
[TBL] [Abstract][Full Text] [Related]
7. Abemaciclib in Combination With Endocrine Therapy for Patients With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Phase 1b Study.
Tolaney SM; Beeram M; Beck JT; Conlin A; Dees EC; Puhalla SL; Rexer BN; Burris HA; Jhaveri K; Helsten T; Becerra C; Kalinsky K; Moore KN; Manuel AM; Lithio A; Price GL; Chapman SC; Litchfield LM; Goetz MP
Front Oncol; 2021; 11():810023. PubMed ID: 35223458
[TBL] [Abstract][Full Text] [Related]
8. Health-Related Quality of Life in MONARCH 3: Abemaciclib plus an Aromatase Inhibitor as Initial Therapy in HR+, HER2- Advanced Breast Cancer.
Goetz MP; Martin M; Tokunaga E; Park IH; Huober J; Toi M; Stoffregen C; Shekarriz S; Andre V; Gainford MC; Price GL; Johnston S
Oncologist; 2020 Sep; 25(9):e1346-e1354. PubMed ID: 32536013
[TBL] [Abstract][Full Text] [Related]
9. Real world incidence and management of adverse events in patients with HR+, HER2- metastatic breast cancer receiving CDK4 and 6 inhibitors in a United States community setting.
Price GL; Sudharshan L; Ryan P; Rajkumar J; Sheffield KM; Nash Smyth E; Morato Guimaraes C; Rybowski S; Cuyun Carter G; Gathirua-Mwangi WG; Huang YJ
Curr Med Res Opin; 2022 Aug; 38(8):1319-1331. PubMed ID: 35535675
[TBL] [Abstract][Full Text] [Related]
10. Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial.
Tolaney SM; Wardley AM; Zambelli S; Hilton JF; Troso-Sandoval TA; Ricci F; Im SA; Kim SB; Johnston SR; Chan A; Goel S; Catron K; Chapman SC; Price GL; Yang Z; Gainford MC; André F
Lancet Oncol; 2020 Jun; 21(6):763-775. PubMed ID: 32353342
[TBL] [Abstract][Full Text] [Related]
11. Safety in Japanese Advanced Breast Cancer Patients Who Received Abemaciclib in MONARCH 2 and MONARCH 3: Assessment of Treatment-Emergent Neutropenia, Diarrhea, and Increased Alanine Aminotransferase and Aspartate Aminotransferase Levels.
Masuda N; Chen Y; Kawaguchi T; Dozono K; Toi M
Cancer Manag Res; 2022; 14():1179-1194. PubMed ID: 35342308
[TBL] [Abstract][Full Text] [Related]
12. Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with HR+, HER2+ advanced breast cancer: plain language summary of the monarcHER study.
Tolaney SM; Goel S; Appiah AK; Huynh T; Chen Y; André F
Future Oncol; 2023 Nov; 19(35):2341-2348. PubMed ID: 37788154
[TBL] [Abstract][Full Text] [Related]
13. Health-Related Quality of Life in MONARCH 2: Abemaciclib plus Fulvestrant in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer After Endocrine Therapy.
Kaufman PA; Toi M; Neven P; Sohn J; Grischke EM; Andre V; Stoffregen C; Shekarriz S; Price GL; Carter GC; Sledge GW
Oncologist; 2020 Feb; 25(2):e243-e251. PubMed ID: 32043763
[TBL] [Abstract][Full Text] [Related]
14. Abemaciclib in Combination with Endocrine Therapy for Adjuvant Treatment of Hormone Receptor-Positive, HER2-Negative, Node-Positive Early Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Orozco Leal G; Armstrong N; Kernohan A; Ahmadu C; Coughlan D; McDermott K; Duffy S; O'Meara S; Robinson T; Vale L; Kleijnen J
Pharmacoeconomics; 2023 Jul; 41(7):741-750. PubMed ID: 36952138
[TBL] [Abstract][Full Text] [Related]
15. Abemaciclib: The Newest CDK4/6 Inhibitor for the Treatment of Breast Cancer.
Palumbo A; Lau G; Saraceni M
Ann Pharmacother; 2019 Feb; 53(2):178-185. PubMed ID: 30099886
[TBL] [Abstract][Full Text] [Related]
16. Open-label, phase II, multicenter study of lasofoxifene plus abemaciclib for treating women with metastatic ER+/HER2- breast cancer and an ESR1 mutation after disease progression on prior therapies: ELAINE 2.
Damodaran S; O'Sullivan CC; Elkhanany A; Anderson IC; Barve M; Blau S; Cherian MA; Peguero JA; Goetz MP; Plourde PV; Portman DJ; Moore HCF
Ann Oncol; 2023 Dec; 34(12):1131-1140. PubMed ID: 38072513
[TBL] [Abstract][Full Text] [Related]
17. Real-World Patient Characteristics, Utilization Patterns, and Outcomes of US Patients with HR+, HER2- Metastatic Breast Cancer Treated with Abemaciclib.
Smyth EN; Beyrer J; Saverno KR; Hadden E; Abedtash H; DeLuca A; Lawrence GW; Rybowski S
Drugs Real World Outcomes; 2022 Dec; 9(4):681-693. PubMed ID: 36097254
[TBL] [Abstract][Full Text] [Related]
18. An open label, randomized phase 2 trial assessing the impact of food on the tolerability of abemaciclib in patients with advanced breast cancer.
Lim E; Boyle F; Okera M; Loi S; Goksu SS; van Hal G; Chapman SC; Gable JC; Chen Y; Price GL; Hossain AM; Gainford MC; Ezquerra MB
Breast Cancer Res Treat; 2022 Oct; 195(3):275-287. PubMed ID: 35915198
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Safety and Treatment Continuity of Palbociclib and Abemaciclib for Hormone Receptor-Positive, HER2-Negative Metastatic/Recurrent Breast Cancer.
Go M; Kimura M; Yamada S; Usami E; Noguchi Y; Yoshimura T
J Pharm Pract; 2024 Apr; ():8971900241247653. PubMed ID: 38652858
[No Abstract] [Full Text] [Related]
20. Abemaciclib: The First FDA-Approved CDK4/6 Inhibitor for the Adjuvant Treatment of HR+ HER2- Early Breast Cancer.
Raheem F; Ofori H; Simpson L; Shah V
Ann Pharmacother; 2022 Feb; ():10600280211073322. PubMed ID: 35135362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]